The Evolving Treatment Landscape of Metastatic Urothelial Carcinoma

Expert oncologists navigate the evolving treatment landscape of advanced or metastatic urothelial carcinoma.

EP. 1: The Landscape of Advanced Urothelial Carcinoma

December 23rd 2021

A brief overview of the advanced urothelial carcinoma landscape encompassing disease course and standard of care treatment strategies.

EP. 2: Treatment Options for Newly Diagnosed Metastatic Urothelial Carcinoma

January 11th 2022

Expert perspectives on optimal treatment approaches in patients with newly diagnosed metastatic urothelial carcinoma.

EP. 3: Impact of Maintenance Therapy on Metastatic Urothelial Carcinoma

January 11th 2022

The overall impact that maintenance therapy has had on patient outcomes in advanced or metastatic urothelial carcinoma.

EP. 4: Metastatic Urothelial Carcinoma: Interpreting JAVELIN Bladder 100

January 18th 2022

A review of the JAVELIN Bladder 100 trial, which evaluated avelumab maintenance therapy following frontline chemotherapy in metastatic urothelial carcinoma.

EP. 5: Practical Advice on Use of Maintenance Therapy in mUC

January 18th 2022

Practical advice on maintenance therapy in metastatic urothelial carcinoma, covering patient education, duration of therapy, and clinical guidelines.

EP. 6: Metastatic Urothelial Carcinoma: Second-Line Therapy and Beyond

January 25th 2022

Expert perspectives on novel treatment approaches being investigated in the second-line setting of metastatic urothelial carcinoma and beyond.

EP. 7: Key Takeaways on the Management of Metastatic Urothelial Carcinoma

January 25th 2022

Clinical pearls of advice regarding the optimal management of metastatic urothelial carcinoma in today’s treatment landscape.

EP. 8: A Global View on Metastatic Urothelial Carcinoma

February 2nd 2022

Expert perspective on the current treatment paradigm of metastatic urothelial carcinoma across different regions of the world.

EP. 9: Immunotherapy’s Roles in Treating Metastatic Urothelial Carcinoma

February 2nd 2022

Considerations for the role of immunotherapy in metastatic urothelial carcinoma as maintenance or switch therapy.

EP. 10: Interpreting JAVELIN Bladder 100: Avelumab in Metastatic Urothelial Carcinoma

February 9th 2022

Ignacio Duran, MD, PhD, reflects on the JAVELIN Bladder 100 trial, which analyzed avelumab as frontline maintenance therapy in metastatic urothelial carcinoma.